An open-label, Multiple Ascending Dose (MAD) study of the selective BRAF inhibitor RO5212054 (PLX3603) to evaluate safety, tolerability and pharmacokinetics in patients with BRAF V600-mutated advanced solid tumours

Cancer type: Solide tumores

Phase: I

Principal Investigator: Lassen Ulrik

Country: DK

Keywords: Denmark, Rigshospitalet, Braf V600 mutation, melanoma, solid tumors, Phase I

Status: Inclusion completed

Link to